GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 59 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $427,816,000 | +122.4% | 6,282,173 | +4.4% | 0.01% | +160.0% |
| Q2 2022 | $192,321,000 | -7.8% | 6,019,431 | -0.1% | 0.01% | 0.0% |
| Q1 2022 | $208,680,000 | +19.0% | 6,024,262 | +0.5% | 0.01% | +25.0% |
| Q4 2021 | $175,420,000 | +18.4% | 5,993,142 | +3.1% | 0.00% | 0.0% |
| Q3 2021 | $148,151,000 | -27.8% | 5,814,399 | -0.8% | 0.00% | -20.0% |
| Q2 2021 | $205,309,000 | -9.7% | 5,862,619 | +5.1% | 0.01% | -16.7% |
| Q1 2021 | $227,253,000 | -3.9% | 5,576,755 | +2.1% | 0.01% | -14.3% |
| Q4 2020 | $236,493,000 | -19.5% | 5,460,482 | +2.5% | 0.01% | -30.0% |
| Q3 2020 | $293,762,000 | -15.7% | 5,327,575 | -3.5% | 0.01% | -16.7% |
| Q2 2020 | $348,451,000 | +23.4% | 5,519,586 | -0.2% | 0.01% | 0.0% |
| Q1 2020 | $282,436,000 | -35.1% | 5,528,195 | +1.0% | 0.01% | -20.0% |
| Q4 2019 | $434,926,000 | +59.8% | 5,471,462 | -2.5% | 0.02% | +50.0% |
| Q3 2019 | $272,177,000 | -3.6% | 5,609,590 | +4.5% | 0.01% | -9.1% |
| Q2 2019 | $282,258,000 | +9.3% | 5,366,126 | +10.0% | 0.01% | +10.0% |
| Q1 2019 | $258,313,000 | +36.7% | 4,880,260 | +6.0% | 0.01% | +25.0% |
| Q4 2018 | $189,027,000 | +18.4% | 4,604,802 | +9.6% | 0.01% | +33.3% |
| Q3 2018 | $159,693,000 | -13.7% | 4,202,443 | +2.6% | 0.01% | -25.0% |
| Q2 2018 | $185,063,000 | -0.8% | 4,094,306 | +6.0% | 0.01% | 0.0% |
| Q1 2018 | $186,570,000 | +44.7% | 3,862,737 | +17.9% | 0.01% | +33.3% |
| Q4 2017 | $128,930,000 | +29.3% | 3,276,485 | +2.0% | 0.01% | +20.0% |
| Q3 2017 | $99,694,000 | +24.3% | 3,210,777 | +9.5% | 0.01% | +25.0% |
| Q2 2017 | $80,224,000 | -14.2% | 2,933,251 | +15.7% | 0.00% | -20.0% |
| Q1 2017 | $93,451,000 | +257.4% | 2,535,980 | +40.1% | 0.01% | +400.0% |
| Q4 2016 | $26,148,000 | -23.1% | 1,809,614 | +22.8% | 0.00% | -50.0% |
| Q3 2016 | $33,981,000 | +60.2% | 1,474,200 | +15.3% | 0.00% | +100.0% |
| Q2 2016 | $21,209,000 | +60.1% | 1,278,464 | +53.1% | 0.00% | 0.0% |
| Q1 2016 | $13,244,000 | -18.7% | 835,024 | +65.8% | 0.00% | 0.0% |
| Q4 2015 | $16,284,000 | -88.5% | 503,659 | -88.5% | 0.00% | -80.0% |
| Q3 2015 | $141,613,000 | – | 4,362,792 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |